January 14, 2026 — Leads & Copy —
MindWalk Holdings Corp. (Nasdaq: HYFT) has announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a protein implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer’s disease.
According to the company, the work demonstrates MindWalk’s ability to discriminate between toxic protein conformations and their healthy counterparts, a challenge in neurodegenerative drug development. The company is resolving the structural and functional logic of neurodegeneration and converting that understanding into selective, biological assets, by defining the disease-driving structural state and anchoring it in bio-native wet-lab validation.
Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk, said that this discovery validates their platform strategy. She added that they are identifying disease-defining protein states and translating that insight into selective, validated assets with traceable biological evidence behind them.
The company states that beyond the specific biology, the study provides external validation of MindWalk’s platform capabilities in a client-driven setting and reinforces the Company’s position as a trusted discovery partner for complex neurodegenerative programs.
The full scientific study, Rational Generation of Monoclonal Antibodies and Intrabodies Selective for Pathogenic TDP-43, is available on bioRxiv (DOI: 10.1101/2025.06.10.658846).
MindWalk is described in the press release as a Bio-Native AI company transforming drug discovery and development. Powered by its patented HYFT® technology and LensAI™ platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with a fully integrated wet-lab. The platform enables rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics to convert insight into validated candidates with speed and precision.
Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk.
Source: MindWalk
